Key Developments

On April 10, 2024, Myonex, a global clinical trial supply company, announced that it hadcompleted its acquisition of Saveway Compounding Pharmacy. The acquisition allow Myonex to better supply patients in clinical trials with medication and equipment as needed. It will also help the company expand its clinical trial designs and include direct-to-patient and home healthcare provider capabilities.
In November 2023, Precision Compounding Pharmacy, a technology-enabled compounding pharmacy that fulfills telemedicine prescriptions, announced that it had received a seed investment from Right Side Capital Management, a technology investment firm. The funds will allow Precision Compounding Pharmacy to enhance its suite of services, broaden its reach, and drive innovation in the pharmacy industry.
In July 2022, Fagron, the leading global player in pharmaceutical compounding, acquired a 503B outsourcing facility from Fresenius Kabi in Boston. With this acquisition, Fagron expanded its U.S. sterile compounding footprint.
In June 2022, Osceola Capital, a private equity firm, announced the eighth addition to the Revelation Pharma Corporation platform by purchasing Wedgewood Pharmacy’s human health book of business. Wedgewood Pharmacy operates compounding pharmacies that offer sterile and non-sterile compounded medications for animal patients in 50 states.
In March 2021, the National Association of Boards of Pharmacy (NABP) announced that it had launched Compounding Pharmacy Information-Sharing Project with U.S. Food and drug Administration
In March 2021, Osceola Capital, a lower middle-market private equity firm, announced the formation of Revelation Pharma Corp. to pursue investments and partnerships across the pharmacy compounding market in partnership with industry executives